Form 4: Enliven Therapeutics CSO Sells $3.47M in Stock

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 132,500 shares of common stock for approximately $3.47 million in early January 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported sales of common stock.
• A total of 132,500 shares were sold across four separate transactions on January 8, 2026, and January 9, 2026.
• The sales were executed at weighted average prices ranging from $20.1282 to $29.1343 per share.
• The total proceeds from these sales amounted to approximately $3,476,008.21.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted by Mr. Lyssikatos on November 15, 2024.
• Following these transactions, Mr. Lyssikatos's indirect beneficial ownership, held through The Lyssikatos Revocable Trust, stands at 765,188 shares of common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling by a key executive. However, the negative impact is mitigated by the fact that the sales were conducted under a pre-arranged 10b5-1 trading plan, suggesting a planned divestment rather than a reaction to adverse company-specific news.

Positives

• The sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to market conditions or new information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.
• The Chief Scientific Officer sold a significant number of shares (132,500), representing a notable reduction in his beneficial ownership.

Risks

• No specific risks were detailed in this Form 4 filing beyond the general market perception associated with insider selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

Industry Context

Insider transaction reports like Form 4 are routine disclosures in the U.S. equity markets, providing transparency into the trading activities of company executives and directors. In the biotechnology and pharmaceutical sectors, such filings are closely watched for signals regarding management's confidence, although pre-arranged 10b5-1 plans often indicate personal financial planning rather than a change in company fundamentals.

Comparison to Industry Standards

• This Form 4 reports a standard insider transaction, common across all industries, where an executive sells shares for personal liquidity or diversification.
• The use of a Rule 10b5-1 trading plan is a common practice among executives to mitigate accusations of insider trading by pre-scheduling sales, aligning with best practices for corporate governance in publicly traded companies.

Corporate Governance

Related Party Transactions

• The shares are held by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee, indicating a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider selling as a potential lack of confidence, although the 10b5-1 plan suggests a pre-planned financial decision.
• The reduction in the Chief Scientific Officer's direct equity stake could be viewed as a slight decrease in alignment of interests with other shareholders.

Next Steps

• No specific future actions, events, or milestones were mentioned in this Form 4 filing.

Key Dates

Recommendation

The insider selling by the Chief Scientific Officer, while significant in volume, was executed under a pre-arranged 10b5-1 plan. This suggests a planned financial move for diversification or liquidity rather than a reaction to new, negative company-specific information. While insider selling can be a yellow flag, the pre-planned nature mitigates immediate alarm. Without additional context on company performance or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future developments and broader market trends rather than making an immediate buy or sell decision based solely on this Form 4.

Keywords

Enliven Therapeutics, ELVN, Insider Sale, Form 4, Joseph P. Lyssikatos, Chief Scientific Officer, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals